See the Complete Picture.
Get Started
SubscribeLogin
Israel-Hamas Conflict
Eurovision
Social Media
Soccer
Disney
Natural Disasters
Donald Trump
Formula 1
South America
Artificial Intelligence
Netflix
Military
Cannes Film Festival
Published • loading... • Updated

Duchenne muscular dystrophy gene therapy demonstrates improved motor functions

Summary by contemporarypediatrics.com
Delandistrogene moxeparvovec-rokl (ELEVIDYS) showed significant motor function improvements in 8- to 9-year-old Duchenne muscular dystrophy patients in part 2 of the phase 3 EMBARK study.
DisclaimerThis story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.

1 Articles

All
Left
Center
Right
contemporarypediatrics.comcontemporarypediatrics.com

Duchenne muscular dystrophy gene therapy demonstrates improved motor functions

Delandistrogene moxeparvovec-rokl (ELEVIDYS) showed significant motor function improvements in 8- to 9-year-old Duchenne muscular dystrophy patients in part 2 of the phase 3 EMBARK study.

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • There is no tracked Bias information for the sources covering this story.
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

contemporarypediatrics.com broke the news in on Friday, May 16, 2025.
Sources are mostly out of (0)
Stories disproportionately reported by the Left or the Right

Similar News Topics

News
For You
SearchBlindspotLocal